logo
  

AzurRx Announces Acquisition Of First Wave Bio, And Creation Of First Wave BioPharma

AzurRx BioPharma, Inc. (AZRX) has agreed to acquire First Wave Bio, Inc. in a stock and cash deal valued at $229 million. AzurRx will change its corporate name to First Wave BioPharma Inc., and will trade common shares on Nasdaq under ticker symbol, FWBI.

First Wave Bio is a clinical-stage biotechnology company specializing in the development of gut-targeted, small molecule therapies for auto-immune inflammatory bowel diseases and other serious conditions.

AzurRx will wholly own all rights to First Wave Bio's formulations of niclosamide, a small molecule drug which features anti-viral and anti-inflammatory properties that are designed to address multiple gastrointestinal conditions.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Covid vaccine makers Pfizer Inc. and BioNTech SE announced a new $3.2 billion vaccine supply deal with the U.S. Government, as the country is bracing for a Covid outbreak this fall. Under the deal, the U.S. government will receive 105 million doses (30 µg, 10 µg and 3 µg) of Pfizer -BioNTech covid vaccines initially. The order may include adult Omicron-adapted COVID-19 vaccines. Samsung Electronics Co. has started the initial mass production of 3-nanometer or nm chips, which is considered as the most advanced chip in the world. In its move, the South Korean tech major beats rival Taiwan Semiconductor Manufacturing Co., the world's largest chip manufacturer, which is reportedly in the process to build one. Bryant Ranch Prepack Inc. is recalling certain Morphine Sulfate Extended-Release Tablets citing incorrect labeling, the U.S. Food and Drug Administration said. The recall involves one lot of Morphine Sulfate 30 mg Extended-Release tablets, and one lot of Morphine Sulfate 60 mg Extended-Release tablets to the consumer level.
Follow RTT